EA201690755A1 - Солевые и кристаллические формы ингибитора plk-4 - Google Patents
Солевые и кристаллические формы ингибитора plk-4Info
- Publication number
- EA201690755A1 EA201690755A1 EA201690755A EA201690755A EA201690755A1 EA 201690755 A1 EA201690755 A1 EA 201690755A1 EA 201690755 A EA201690755 A EA 201690755A EA 201690755 A EA201690755 A EA 201690755A EA 201690755 A1 EA201690755 A1 EA 201690755A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compound
- salt
- crystal forms
- fumarate
- maleate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Раскрыты фумаратная соль и малеатная соль соединения (I), представленного приведенной ниже структурной формулой, а также соответствующие фармацевтические композиции на их основе. Конкретные монокристаллические формы 1:1 фумарата соединения (I) и 1:1 малеата соединения (I) характеризуются рядом свойств и физических параметров. Также раскрыты способы получения монокристаллических форм 1:1 фумарата соединения (I) и 1:1 малеата соединения (I). Настоящее изобретение также относится к способам лечения субъекта со злокачественной опухолью.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361892564P | 2013-10-18 | 2013-10-18 | |
PCT/CA2014/051001 WO2015054793A1 (en) | 2013-10-18 | 2014-10-17 | Salt and crystal forms of plk-4 inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201690755A1 true EA201690755A1 (ru) | 2016-09-30 |
EA031569B1 EA031569B1 (ru) | 2019-01-31 |
Family
ID=52827507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690755A EA031569B1 (ru) | 2013-10-18 | 2014-10-17 | Солевые и кристаллические формы ингибитора plk-4 |
Country Status (26)
Country | Link |
---|---|
US (5) | US9884855B2 (ru) |
EP (1) | EP3057965B1 (ru) |
JP (1) | JP6492072B2 (ru) |
KR (3) | KR102395737B1 (ru) |
CN (2) | CN105764899B (ru) |
AU (1) | AU2014336929B9 (ru) |
CA (1) | CA2926845C (ru) |
CY (1) | CY1121484T1 (ru) |
DK (1) | DK3057965T3 (ru) |
EA (1) | EA031569B1 (ru) |
ES (1) | ES2718603T3 (ru) |
HR (1) | HRP20190564T1 (ru) |
HU (1) | HUE043194T2 (ru) |
IL (1) | IL245038B (ru) |
LT (1) | LT3057965T (ru) |
ME (1) | ME03377B (ru) |
MX (1) | MX359069B (ru) |
NZ (1) | NZ718744A (ru) |
PL (1) | PL3057965T3 (ru) |
PT (1) | PT3057965T (ru) |
RS (1) | RS58413B1 (ru) |
SG (1) | SG11201602783SA (ru) |
SI (1) | SI3057965T1 (ru) |
TR (1) | TR201902875T4 (ru) |
TW (1) | TWI659952B (ru) |
WO (1) | WO2015054793A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2417127B1 (en) | 2009-04-06 | 2014-02-26 | University Health Network | Kinase inhibitors and method of treating cancer with same |
BR112012025496B1 (pt) | 2010-04-06 | 2021-02-23 | University Health Network | composto inibidor quinase e composição farmacêutica que o compreende |
ES2718603T3 (es) | 2013-10-18 | 2019-07-03 | Univ Health Network | Sal y formas cristalinas de inhibidor de PLK-4 |
AU2018328773B2 (en) * | 2017-09-08 | 2023-11-16 | University Health Network | Combination therapies for inhibition of Polo-like Kinase 4 |
JP2022530028A (ja) | 2019-04-24 | 2022-06-27 | ユニバーシティー ヘルス ネットワーク | PLK4阻害剤である(1R,2S)-(E)-2-(3-(4-((cis-2,6-ジメチルモルホリノ)メチル)スチリル)-1H-イミダゾール-6-イル)-5’-メトキシスピロ[シクロプロパン-1,3’-インドリン]-2’-オンフマル酸塩のS4結晶形 |
JP2023505301A (ja) * | 2019-12-06 | 2023-02-08 | ユニバーシティー ヘルス ネットワーク | 急性骨髄性白血病または骨髄異形成症候群に対する治療 |
AU2022272184A1 (en) | 2021-05-11 | 2023-11-30 | Oric Pharmaceuticals, Inc. | Polo like kinase 4 inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2483323A (en) * | 1945-08-01 | 1949-09-27 | Kay Fries Chemicals Inc | Method of preparing phenyl ethyl alcohol |
AU2003286604A1 (en) | 2002-10-21 | 2004-05-13 | Irm Llc | Oxindoles with anti-hiv activity |
DE102005005395A1 (de) | 2005-02-03 | 2006-08-10 | Schering Aktiengesellschaft | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
GB0606234D0 (en) * | 2006-03-29 | 2006-05-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutically acceptable salts and polymorphic forms |
WO2008118097A1 (en) * | 2007-03-23 | 2008-10-02 | Agency For Science, Technology And Research | Palladium catalysts |
KR101444924B1 (ko) * | 2007-09-25 | 2014-10-07 | 다케다 야쿠힌 고교 가부시키가이샤 | 폴로형 키나아제 억제제 |
JP2011506494A (ja) * | 2007-12-21 | 2011-03-03 | ユニバーシティ・ヘルス・ネットワーク | 癌の治療に有用なキナーゼ阻害剤としてのインダゾリル、ベンズイミダゾリル、ベンゾトリアゾリル置換インドルモン誘導体 |
EP2417127B1 (en) | 2009-04-06 | 2014-02-26 | University Health Network | Kinase inhibitors and method of treating cancer with same |
WO2010125004A1 (en) | 2009-04-29 | 2010-11-04 | Nerviano Medical Sciences S.R.L. | Cdk inhibitor salts |
BR112012025496B1 (pt) | 2010-04-06 | 2021-02-23 | University Health Network | composto inibidor quinase e composição farmacêutica que o compreende |
EP2588110B1 (en) | 2010-07-02 | 2018-10-17 | University Health Network | Methods of targeting pten mutant diseases and compositions therefor |
WO2012048411A1 (en) | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
CN103476770B (zh) * | 2010-11-25 | 2017-02-15 | 拉蒂欧制药有限责任公司 | 阿法替尼盐和多晶型物 |
EP2766352B1 (en) * | 2011-10-12 | 2018-06-06 | University Health Network (UHN) | Indazole compounds as kinase inhibitors and method of treating cancer with same |
ES2718603T3 (es) | 2013-10-18 | 2019-07-03 | Univ Health Network | Sal y formas cristalinas de inhibidor de PLK-4 |
MX357763B (es) | 2013-10-18 | 2018-07-23 | Univ Health Network | Tratamiento para cancer pancreatico. |
-
2014
- 2014-10-17 ES ES14854037T patent/ES2718603T3/es active Active
- 2014-10-17 ME MEP-2019-97A patent/ME03377B/me unknown
- 2014-10-17 LT LTEP14854037.0T patent/LT3057965T/lt unknown
- 2014-10-17 KR KR1020217036751A patent/KR102395737B1/ko active IP Right Grant
- 2014-10-17 TW TW103135953A patent/TWI659952B/zh active
- 2014-10-17 DK DK14854037.0T patent/DK3057965T3/en active
- 2014-10-17 PT PT14854037T patent/PT3057965T/pt unknown
- 2014-10-17 US US15/029,373 patent/US9884855B2/en active Active
- 2014-10-17 EP EP14854037.0A patent/EP3057965B1/en active Active
- 2014-10-17 CN CN201480064037.9A patent/CN105764899B/zh active Active
- 2014-10-17 TR TR2019/02875T patent/TR201902875T4/tr unknown
- 2014-10-17 WO PCT/CA2014/051001 patent/WO2015054793A1/en active Application Filing
- 2014-10-17 JP JP2016524077A patent/JP6492072B2/ja active Active
- 2014-10-17 SG SG11201602783SA patent/SG11201602783SA/en unknown
- 2014-10-17 SI SI201431110T patent/SI3057965T1/sl unknown
- 2014-10-17 PL PL14854037T patent/PL3057965T3/pl unknown
- 2014-10-17 RS RS20190269A patent/RS58413B1/sr unknown
- 2014-10-17 MX MX2016004963A patent/MX359069B/es active IP Right Grant
- 2014-10-17 HU HUE14854037A patent/HUE043194T2/hu unknown
- 2014-10-17 KR KR1020227015022A patent/KR20220063299A/ko not_active Application Discontinuation
- 2014-10-17 CA CA2926845A patent/CA2926845C/en active Active
- 2014-10-17 KR KR1020167012155A patent/KR20160070106A/ko not_active Application Discontinuation
- 2014-10-17 AU AU2014336929A patent/AU2014336929B9/en active Active
- 2014-10-17 CN CN202110510808.4A patent/CN113248486A/zh active Pending
- 2014-10-17 EA EA201690755A patent/EA031569B1/ru not_active IP Right Cessation
- 2014-10-17 NZ NZ718744A patent/NZ718744A/en unknown
-
2016
- 2016-04-11 IL IL24503816A patent/IL245038B/en active IP Right Grant
-
2018
- 2018-02-01 US US15/886,104 patent/US10392374B2/en active Active
-
2019
- 2019-03-22 HR HRP20190564TT patent/HRP20190564T1/hr unknown
- 2019-03-22 CY CY20191100336T patent/CY1121484T1/el unknown
- 2019-04-19 US US16/389,119 patent/US10472353B2/en active Active
- 2019-11-06 US US16/675,609 patent/US10919886B2/en active Active
-
2021
- 2021-02-10 US US17/172,511 patent/US11667627B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690755A1 (ru) | Солевые и кристаллические формы ингибитора plk-4 | |
EA201690153A1 (ru) | Замещенные бензофуранильные и бензоксазолильные соединения и их применения | |
EA201690094A1 (ru) | Ингибиторы syk | |
EA201491824A1 (ru) | Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1 | |
EA201690989A1 (ru) | Ингибиторы syk | |
EA201990833A1 (ru) | Соединение пиридина | |
EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
EA201490747A1 (ru) | 1-арилкарбонил-4-оксипиперидиновые соединения, полезные для лечения нейродегенеративных заболеваний | |
EA201491012A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
EA202190619A1 (ru) | Противовирусные соединения | |
EA201690204A1 (ru) | Соединения n,6-бис(арил или гетероарил)-1,3,5-триазин-2,4-диамина в качестве ингибиторов мутантов idh2 для лечения ракового заболевания | |
EA201490474A1 (ru) | Аминохиназолины в качестве ингибиторов киназ | |
EA201491672A1 (ru) | Гетероциклильные соединения как ингибиторы mek | |
PH12016500225B1 (en) | Novel quinoline-substituted compound | |
EA201270752A1 (ru) | Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью | |
EA201491149A1 (ru) | Пиразолопиридиновые производные, способы их получения и их терапевтическое применение | |
MX2016002368A (es) | Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1). | |
EA201892050A1 (ru) | Способ получения замещенных 5-фтор-1h-пиразолопиридинов | |
EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
EA201690844A1 (ru) | Ингибиторы gsk-3 | |
EA201490269A1 (ru) | Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета | |
EA201790337A1 (ru) | Кристаллические формы ингибиторов глутаминазы | |
EA201490650A1 (ru) | Фармацевтические композиции | |
EA201691141A1 (ru) | Соединения против ccr6 | |
EA201590735A1 (ru) | 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |